Michele Kohli

Summary

Publications

  1. doi request reprint Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion
    Michele A Kohli
    Michele A Kohli is a director of health economics and outcomes research at Optum in Burlington, Ontario
    Health Aff (Millwood) 34:1234-40. 2015
  2. pmc Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Michele Kohli
    OptumInsight, Health Economics and Outcomes Research, 5500 North Service Rd, Burlington, ON L7L 6W6, Canada
    BMC Public Health 12:872. 2012

Detail Information

Publications2

  1. doi request reprint Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion
    Michele A Kohli
    Michele A Kohli is a director of health economics and outcomes research at Optum in Burlington, Ontario
    Health Aff (Millwood) 34:1234-40. 2015
    ..Despite its higher price, compared to PCV7, this new vaccine is expected to provide payers with substantial net budgetary savings...
  2. pmc Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Michele Kohli
    OptumInsight, Health Economics and Outcomes Research, 5500 North Service Rd, Burlington, ON L7L 6W6, Canada
    BMC Public Health 12:872. 2012
    ..In this analysis, the estimated clinical and economic benefit of each of these vaccines was compared in the Canadian setting...